(Q44008216)

English

DNA vaccine coding for the rhesus prostate specific antigen delivered by intradermal electroporation in patients with relapsed prostate cancer.

scientific article published on 2 July 2013

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23831327%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

DNA vaccine coding for the rhesus prostate specific antigen delivered by intradermal electroporation in patients with relapsed prostate cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23831327%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

electroporation

1 reference

based on heuristic

inferred from title

Fredrik Eriksson

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23831327%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

author name string

Thomas Tötterman

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23831327%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

Anna-Karin Maltais

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23831327%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

Pavel Pisa

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23831327%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

Jeffrey Yachnin

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23831327%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

language of work or name

0 references

publication date

2 July 2013

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23831327%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

number of pages

6

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23831327%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

31

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23831327%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

37

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23831327%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

3843-3848

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23831327%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.063

7 January 2021

DNA vaccination against tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.063

7 January 2021

Characterization of rhesus monkey prostate specific antigen cDNA

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.063

7 January 2021

Electroporation improves the efficacy of DNA vaccines in large animals

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.063

7 January 2021

DNA vaccination with electroporation induces increased antibody responses in patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.063

7 January 2021

Skin electroporation: effects on transgene expression, DNA persistence and local tissue environment

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.063

7 January 2021

In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.063

7 January 2021

Mechanism of immunosuppression in males following trauma-hemorrhage. Critical role of testosterone.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.063

7 January 2021

T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.063

7 January 2021

Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.063

7 January 2021

A modified epitope identified for generation and monitoring of PSA-specific T cells in patients on early phases of PSA-based immunotherapeutic protocols

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.063

7 January 2021

Recognition of PSA-derived peptide antigens by T cells from prostate cancer patients without any prior stimulation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.063

7 January 2021

High frequency of prostate antigen-directed T cells in cancer patients compared to healthy age-matched individuals

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.063

7 January 2021

CD8+ T cells specific for the androgen receptor are common in patients with prostate cancer and are able to lyse prostate tumor cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.063

7 January 2021

Radiation therapy induces circulating serum Hsp72 in patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.063

7 January 2021

T cells localized to the androgen-deprived prostate are TH1 and TH17 biased.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.063

7 January 2021

Augmentation of T Cell Levels and Responses Induced by Androgen Deprivation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.063

7 January 2021

Prostate cancer patients on androgen deprivation therapy develop persistent changes in adaptive immune responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.063

7 January 2021

Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.063

7 January 2021

Androgen deprivation boosts prostatic infiltration of cytotoxic and regulatory T lymphocytes and has no effect on disease-free survival in prostate cancer patients.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.063

7 January 2021

Increased CD8+ T-cell function following castration and immunization is countered by parallel expansion of regulatory T cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.063

7 January 2021

Immune monitoring in a phase 1 trial of a PSA DNA vaccine in patients with hormone-refractory prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.063

7 January 2021

Optimization of skin electroporation in mice to increase tolerability of DNA vaccine delivery to patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.063

7 January 2021

Intradermal DNA electroporation induces survivin-specific CTLs, suppresses angiogenesis and confers protection against mouse melanoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.063

7 January 2021

Enhancement of cellular immune response to a prostate cancer DNA vaccine by intradermal electroporation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.063

7 January 2021

Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.063

7 January 2021

Vaccination with agonist peptide PSA: 154-163 (155L) derived from prostate specific antigen induced CD8 T-cell response to the native peptide PSA: 154-163 but failed to induce the reactivity against tumor targets expressing PSA: a phase 2 study in p

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.063

7 January 2021

Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.063

7 January 2021

Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.063

7 January 2021

Identifiers

10.1016/J.VACCINE.2013.06.063

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23831327%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23831327%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44008216&oldid=2105596239"